Michael Shokhen

Prof. Dr. Michael Shokhen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Valery A. PetrenkoValery A. Petrenko
Valery A. Petrenko
JGJames Gillespie
James Gillespie
Laura Maria De PlanoLaura Maria De Plano
Laura Maria De Plano
MSMichael Shokhen
Michael Shokhen
The evolution of the SARS-CoV-2 virus during the COVID-19 pandemic was accompanied by the emergence of new heavily mutated viral variants with increased infectivity and/or resistance to detection by the human immune system. To respond to the urgent need for advanced methods and materials to empower a better understanding of the mechanisms of virus’s adaptation to human host cells and to the immuno-resistant human population, we suggested using recombinant filamentous bacteriophages, displaying on their surface foreign peptides termed “mimotopes”, which mimic the structure of viral receptor-binding sites on the viral spike protein and can serve as molecular probes in the evaluation of molecular mechanisms of virus infectivity. In opposition to spike-binding antibodies that are commonly used in studying the interaction of the ACE2 receptor with SARS-CoV-2 variants in vitro, phage spike mimotopes targeted to other cellular receptors would allow discovery of their role in viral infection in vivo using cell culture, tissue, organs, or the whole organism. Phage mimotopes of the SARS-CoV-2 Spike S1 protein have been developed using a combination of phage display and molecular mimicry concepts, termed here “phage mimicry”, supported by bioinformatics methods. The key elements of the phage mimicry concept include: (1) preparation of a collection of p8-type (landscape) phages, which interact with authentic active receptors of live human cells, presumably mimicking the binding interactions of human coronaviruses such as SARS-CoV-2 and its variants; (2) discovery of closely related amino acid clusters with similar 3D structural motifs on the surface of natural ligands (FGF1 and NRP1), of the model receptor of interest FGFR and the S1 spike protein; and (3) an ELISA analysis of the interaction between candidate phage mimotopes with FGFR3 (a potential alternative receptor) in comparison with ACE2 (the authentic receptor).

21 December 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
NUNeta Uritsky
Neta Uritsky
MSMichael Shokhen
Michael Shokhen
AAAmnon Albeck
Amnon Albeck

24 October 2017 in Protein Science
Verified
Journal Article
Closed access
PDF file
MSMichael Shokhen
Michael Shokhen
AAAmnon Albeck
Amnon Albeck

12 May 2014 in Israel Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
MSMichael Shokhen
Michael Shokhen
MHMichal Hirsch
Michal Hirsch
NKNetaly Khazanov
Netaly Khazanov
RORachel Ozeri
Rachel Ozeri
NPNurit Perlman
Nurit Perlman
AAAmnon Albeck
Amnon Albeck

20 April 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Open access
MSMichael Shokhen
Michael Shokhen
RWRandall Walikonis
Randall Walikonis
VUVladimir N. Uversky
Vladimir N. Uversky
AAAmnon Allbeck
Amnon Allbeck
CZCamryn Zezelic
Camryn Zezelic
ALAndrew Levy
Andrew Levy
IQSEC2 gene mutations are associated with epilepsy, autism, and intellectual disability. The primary function IQSEC2, mediated via its Sec 7 domain, is to act as a guanine nucleotide exchange factor for ARF6. We sought to develop a molecular model, which may explain the aberrant Sec 7 activity on ARF6 of different human IQSEC2 mutations. We integrated experimental data of IQSEC2 mutants with protein structure prediction by the RaptorX server combined with molecular modeling and molecular dynamics simulations. Normally, apocalmodulin (apoCM) binds to IQSEC2 resulting in its N-terminal fragment inhibiting access of its Sec 7 domain to ARF6. An increase in Ca2+ concentration destabilizes the interaction of IQSEC2 with apoCM and removes steric hindrance of Sec 7 binding with ARF6. Mutations at amino acid residue 350 of IQSEC2 result in loss of steric hindrance of Sec 7 binding with ARF6 leading to constitutive activation of ARF6 by Sec 7. On the other hand, a mutation at amino acid residue 359 of IQSEC2 results in constitutive hindrance of Sec 7 binding to ARF6 leading to the loss of the ability of IQSEC2 to activate ARF6. These studies provide a model for dysregulation of IQSEC2 Sec 7 activity by mutant IQSEC2 proteins. Communicated by Ramaswamy H. Sarma

1 April 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TTTamar Traube
Tamar Traube
MSMichael Shokhen
Michael Shokhen
AAAmnon Albeck
Amnon Albeck